Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2020 - Issue
Submit an article Journal homepage
168
Views
6
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study

Tanja Plate1 AstraZeneca GmbH, Wedel, GermanyORCID Iconhttps://orcid.org/0000-0001-8697-6458
ORCID Icon,
Felix W Friedrich1 AstraZeneca GmbH, Wedel, GermanyCorrespondence[email protected]
&
Jutta Beier2 Insaf - Respiratory Research Institute GmbH, Wiesbaden, GermanyORCID Iconhttps://orcid.org/0000-0002-8254-7936
ORCID Icon
Pages 1335-1347 | Published online: 10 Jun 2020

Figures & data

Table 1 Patients' Demographic and Anamnestic Data (AB/FF, n=2121; GLY/IND, n=1056; UME/VL, n=476)

Figure 1 LABA/LAMA fixed-dose therapy at baseline (n=3653).

Abbreviations: LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists.

Figure 1 LABA/LAMA fixed-dose therapy at baseline (n=3653).Abbreviations: LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists.

Figure 2 Premature termination of treatment or study (AB/FF, n=2136; GLY/IND, n=1079; UME/VL, n=495). (A) Number of patients who discontinued therapy or study. (B) Most frequent reasons for termination.

Figure 2 Premature termination of treatment or study (AB/FF, n=2136; GLY/IND, n=1079; UME/VL, n=495). (A) Number of patients who discontinued therapy or study. (B) Most frequent reasons for termination.

Table 2 Frequency and Severity of Exacerbations During the Study (Patients with Follow-Up Visits; AB/FF, n=1969; GLY/IND, n=1000; UME/VL, n=439)

Figure 3 Lung function during the observational time (LOFC values). (A) Mean FEV1. (B) Mean FVC.

Abbreviations: LOCF, Last Observation Carried Forward Method; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
Figure 3 Lung function during the observational time (LOFC values). (A) Mean FEV1. (B) Mean FVC.

Figure 4 Well-being and quality of life. Mean CAT™ score during the study (LOCF).

Note: 0=normal – 40=very strong symptoms.
Abbreviations: CAT™, COPD Assessment Test; LOCF, Last Observation Carried Forward Method.
Figure 4 Well-being and quality of life. Mean CAT™ score during the study (LOCF).

Figure 5 Overall severity of early morning COPD symptoms during the course of the study (LOCF).

Note: 0=no symptoms – 4=very severe.
Abbreviation: LOCF, Last Observation Carried Forward Method.
Figure 5 Overall severity of early morning COPD symptoms during the course of the study (LOCF).

Table 3 Category of Adverse Events and Frequency of Patients Affected (AB/FF, n=2136; GLY/IND, n=1079; UME/VL, n=495)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.